Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide.

Hunter FW, Devaux JBL, Meng F, Hong CR, Khan A, Tsai P, Ketela TW, Sharma I, Kakadia PM, Marastoni S, Shalev Z, Hickey AJR, Print CG, Bohlander SK, Hart CP, Wouters BG, Wilson WR.

Mol Pharmacol. 2019 Jun;95(6):638-651. doi: 10.1124/mol.118.115196. Epub 2019 Apr 12.

PMID:
30979813
2.

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.

Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Grénman RA, Caporiccio L, McKee TD, Zaidi M, Butt S, Macann AM, McIvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW.

JCI Insight. 2018 Aug 23;3(16). pii: 122204. doi: 10.1172/jci.insight.122204. eCollection 2018 Aug 23.

3.

Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.

Hong CR, Dickson BD, Jaiswal JK, Pruijn FB, Hunter FW, Hay MP, Hicks KO, Wilson WR.

Biochem Pharmacol. 2018 Oct;156:265-280. doi: 10.1016/j.bcp.2018.08.027. Epub 2018 Aug 19.

PMID:
30134191
4.

Antagonism in effectiveness of evofosfamide and doxorubicin through intermolecular electron transfer.

Anderson RF, Li D, Hunter FW.

Free Radic Biol Med. 2017 Dec;113:564-570. doi: 10.1016/j.freeradbiomed.2017.10.385. Epub 2017 Oct 28.

PMID:
29111232
5.

Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.

Hunter FW, Wouters BG, Wilson WR.

Br J Cancer. 2016 May 10;114(10):1071-7. doi: 10.1038/bjc.2016.79. Epub 2016 Apr 12. Review.

6.

Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.

Hunter FW, Young RJ, Shalev Z, Vellanki RN, Wang J, Gu Y, Joshi N, Sreebhavan S, Weinreb I, Goldstein DP, Moffat J, Ketela T, Brown KR, Koritzinsky M, Solomon B, Rischin D, Wilson WR, Wouters BG.

Cancer Res. 2015 Oct 1;75(19):4211-23. doi: 10.1158/0008-5472.CAN-15-1107. Epub 2015 Aug 21.

7.

Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.

Hunter FW, Hsu HL, Su J, Pullen SM, Wilson WR, Wang J.

Mol Cancer Ther. 2014 Nov;13(11):2501-14. doi: 10.1158/1535-7163.MCT-14-0476. Epub 2014 Sep 5.

8.

The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.

Hunter FW, Jaiswal JK, Hurley DG, Liyanage HD, McManaway SP, Gu Y, Richter S, Wang J, Tercel M, Print CG, Wilson WR, Pruijn FB.

Biochem Pharmacol. 2014 May 15;89(2):224-35. doi: 10.1016/j.bcp.2014.03.001. Epub 2014 Mar 13.

PMID:
24632291
9.

Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.

Hunter FW, Wang J, Patel R, Hsu HL, Hickey AJ, Hay MP, Wilson WR.

Biochem Pharmacol. 2012 Mar 1;83(5):574-85. doi: 10.1016/j.bcp.2011.12.005. Epub 2011 Dec 13.

PMID:
22182429
10.

Americans with Disabilities Act: hospitals must comply.

Hunter FW.

South Hosp. 1991 Jan-Feb;57(1):35-6. No abstract available.

PMID:
10170857

Supplemental Content

Loading ...
Support Center